The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II tailored S-1 regimen study of first-line chemotherapy in elderly patients with advanced and recurrent non-small cell lung cancer.
Takayuki Shiroyama
No relevant relationships to disclose
Takashi Kijima
No relevant relationships to disclose
Kiyoshi Komuta
No relevant relationships to disclose
Suguru Yamamoto
No relevant relationships to disclose
Seigo Minami
No relevant relationships to disclose
Yoshitaka Ogata
No relevant relationships to disclose
Kouhei Okafuji
No relevant relationships to disclose
Fumio Imamura
No relevant relationships to disclose
Tomonori Hirashima
No relevant relationships to disclose
Isao Tachibana
No relevant relationships to disclose
Ichiro Kawase
No relevant relationships to disclose
Atsushi Kumanogoh
No relevant relationships to disclose